The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused ...
Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, ...
Cartesian Growth Corporation IV (the 'Company”) announced today the pricing of its initial public offering of 25,000,000 units, at a price of $10.00 per unit. The units are expected to commence ...
BOSTON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Factorial Inc. (“Factorial” or the “Company”), a leader in solid-state battery technology, and Cartesian Growth Corporation III (“Cartesian III”) ...
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results